Literature DB >> 17488687

Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Patricia Martín-Jiménez1, Ramón García-Sanz, Ana Balanzategui, Miguel Alcoceba, Enrique Ocio, Maria Luz Sanchez, Marcos González, Jesus San Miguel.   

Abstract

BACKGROUND AND OBJECTIVES: Waldenström macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS) are IgM-related disorders in which monoclonal B cells harbor a unique clonotypic rearrangement of the immunoglobulin heavy chain gene (IgH). The aim of this study was to characterize IgH rearrangements in a larger series of IgM-related disorders than any previously described. DESIGN AND METHODS: Seventy-two patients with monoclonal IgM disorders (64 with WM and eight with IgM-MGUS) were studied to amplify and sequence both VDJH and DJH rearrangements. Twenty-nine of them were also tested for the existence of class switch recombination (CSR).
RESULTS: VDJH and DJH rearrangements were detected in 91% and 42% of WM patients and in 100% and 13% of IgM-MGUS patients, respectively. In WM, the most frequently observed VH family and single segment were VH3 and VH3-23 (76% and 29%, respectively), with their frequencies differing markedly from those that would occur if the rearrangements were random. The VH3-23 segment was never selected in IgM-MGUS. The distribution of both DH and JH families in WM did not differ from that in normal B-lymphocytes. Somatic hypermutation with >2% deviation was seen in 90% of cases of WM and in 71% of IgM-MGUS. DJH rearrangements were more frequent in WM than in MGUS (42% and 13%, respectively). All DJH rearrangements were unmutated, which makes them an attractive target for minimal residual disease investigation. IgM clonotypic transcripts were observed in all cases and IgD in 83%. IgA and/or IgG monoclonal isotypes were seen in three WM cases (14%) but in none of the IgM-MGUS patients. INTERPRETATION AND
CONCLUSIONS: WM and IgM-MGUS exhibit dissimilarities in VDJH and DJH rearrangements that could suggest different differentiation processes. There is evidence that WM cells are able to undergo CSR in vivo, a fact that was initially thought to be impossible in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488687     DOI: 10.3324/haematol.10755

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Willem Kraan; Marie José Kersten; Steven P Treon; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

3.  Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.

Authors:  Sigurdur Y Kristinsson; Jill Koshiol; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  J Natl Cancer Inst       Date:  2010-02-24       Impact factor: 13.506

4.  Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Prashant Kapoor; Chia-Jen Liu; Efstathios Kastritis; Saurabh Zanwar; Geoffrey Fell; Jithma P Abeykoon; Kalvis Hornburg; Carl Jannes Neuse; Catherine R Marinac; David Liu; Jenny Soiffer; Maria Gavriatopoulou; Cody Boehner; Joseph M Cappuccio; Henry Dumke; Kaitlen Reyes; Robert J Soiffer; Robert A Kyle; Steven P Treon; Jorge J Castillo; Meletios A Dimopoulos; Stephen M Ansell; Lorenzo Trippa; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2019-04-16       Impact factor: 44.544

5.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

Review 7.  Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Authors:  Elisabet E Manasanch; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-07

8.  Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.

Authors:  Ulla Randen; Gunhild Trøen; Anne Tierens; Chloé Steen; Abdirashid Warsame; Klaus Beiske; Geir E Tjønnfjord; Sigbjørn Berentsen; Jan Delabie
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

9.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

10.  TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells.

Authors:  Alexandrine Geffroy-Luseau; David Chiron; Géraldine Descamps; Gaëtan Jégo; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Front Immunol       Date:  2011-12-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.